NextCure, Inc. (NXTC) Earnings History
Annual and quarterly earnings data from 2017 to 2025
Loading earnings history...
NXTC EPS Growth (CAGR)
Compound annual growth rate of diluted earnings per share
CAGR (Compound Annual Growth Rate) shows the annualized growth rate of EPS over the specified period. A higher CAGR indicates stronger earnings momentum.
NXTC Profitability Analysis
Margin trends over time
| Year | Gross Margin | Operating Margin | Net Margin |
|---|---|---|---|
| 2025 | - | - | - |
| 2024 | - | - | - |
| 2023 | - | - | - |
| 2022 | - | - | - |
| 2021 | - | - | - |
Download Data
Export NXTC earnings history in CSV or JSON format
Free sign-in required to download data
NextCure, Inc. (NXTC) Earnings Overview
As of May 8, 2026, NextCure, Inc. (NXTC) reported trailing twelve-month net income of -$55M, reflecting +17.7% year-over-year growth. The company earned $-10.43 per diluted share over the past four quarters.
Looking at the long-term picture, NXTC's historical earnings data spans multiple years. The company achieved its highest annual net income of -$15M in fiscal 2017.
NextCure, Inc. is currently reporting a net loss, though operating performance should be evaluated in the context of growth investments and industry dynamics View revenue history →
Compared to peers including FATE (-$136M net income, -2051.1% margin), RCUS (-$369M net income, -142.9% margin), AGEN ($115,000 net income, 0.1% margin), NXTC has comparable earnings metrics. Compare NXTC vs FATE →
NXTC Earnings vs Peers
Earnings metrics vs comparable public companies
NXTC Historical Earnings Data (2017–2025)
9 years| Fiscal Year | Net Income | YoY % | Operating Income | EPS (Diluted) | Net Margin | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | -$56M | -0.3% | -$58M | $-19.65 | - | - |
| 2024 | -$56M | +11.3% | -$60M | $-23.88 | - | - |
| 2023 | -$63M | +16.1% | -$68M | $-27.04 | - | - |
| 2022 | -$75M | -7.7% | -$76M | $-32.32 | - | - |
| 2021 | -$69M | -89.6% | -$71M | $-30.15 | - | - |
| 2020 | -$37M | -8.5% | -$41M | $-15.95 | -163.6% | -184.2% |
| 2019 | -$34M | -48.0% | -$37M | $-25.79 | -531.5% | -590.5% |
| 2018 | -$23M | -47.4% | -$23M | $-12.04 | - | - |
| 2017 | -$15M | - | -$16M | $-8.17 | - | - |
See NXTC's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs NXTC Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare NXTC vs DBVT
Side-by-side business, growth, and profitability comparison vs DBV Technologies S.A..
Start ComparisonNXTC — Frequently Asked Questions
Quick answers to the most common questions about buying NXTC stock.
Is NXTC growing earnings?
NXTC EPS is $-10.43, with earnings growth accelerating to +17.7%. This exceeds the 5-year CAGR of N/A. TTM net income reached $-55M.
What are NXTC's profit margins?
NextCure, Inc. net margin is N/A, with operating margin at N/A. Below-average margins reflect competitive or cost pressures.
How consistent are NXTC's earnings?
NXTC earnings data spans 2017-2025. The accelerating earnings trend is +17.7% YoY. Historical data enables comparison across business cycles.